Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C152632
http://purl.obolibrary.org/obo/NCIT_C152632
|
|---|---|
| Preferred Name | Tilsotolimod |
| Definitions |
A proprietary synthetic oligonucleotide-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, tilsotolimod binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B-cells. This initiates immune signaling pathways, activates B-cells and pDCs, and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A proprietary synthetic oligonucleotide-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, tilsotolimod binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B-cells. This initiates immune signaling pathways, activates B-cells and pDCs, and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity. |
|---|---|
| prefLabel | Tilsotolimod
|
| label | Tilsotolimod
|
| Has_Salt_Form | |
| NCI_META_CUI | CL553836
|
| code | C152632
|
| Has_Target | |
| prefixIRI | NCIT:C152632
|
| in_subset | |
| Display_Name | Tilsotolimod
|
| Preferred_Name | Tilsotolimod
|
| FDA_UNII_Code | G287IC9MH3
|
| Contributing_Source |
CTRP
FDA
|
| CAS_Registry | 1948266-37-2
|
| type | |
| subClassOf | |
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |